American Journal of Pharmacy and Health Research

Iatrogenic harm induced from medication occur at a rate more than one fourth in general wards and more than three fourth in ICUs, it estimated that during a critical care stay 1.7 medication errors per patient could be potentially life-threatening especially from drug given intravenously. We Aimed to assess the intravenous high-risk medication management in tertiary care hospital, and analyze utilization of IV high-risk medication dilution, diluent and duration. Methods Prospective controlled study involving 250 participants evaluated the utilization patterns of intravenous high-risk medications in equal divided groups, with a focus on dilution practices, diluent selection, and duration of administration in a critical care unit over a period of six months. A researcher observed this study by reviewing all the Patient Infusion Charts, Critical Care Flow Sheet and Syringe pump/infusions. Baseline severity was assessed using APACHE II and qSOFA scores. Categorical variables were analyzed using the Chi-square test. Results A total of 250 participants were enrolled and equally allocated into two groups 125 intervention and 125 Control. Analyzing the baseline clinical severities parameters including APACHE II scores (p = 0.845) and qSofa (p = 0.589) were distinguished between groups. No statistically significant differences were observed in primary clinical outcomes such as mortality (p =0.447) or discharge status (p = 0.609). A researcher independent double-checking before medication administration was documented in 81 (64.8%) intervention patients compared to 79 (63.2%) control patients (p =0.895). Conclusion In conclusion, primary outcomes were statistically distinct between the study groups, pharmacist-led observation and independent double-checking protocols established structured standardization in IV drug dilution, diluent selection, and infusion rate monitoring. Further research using more sensitive methods to assess key variables will provide a clearer and more comprehensive understanding of the true impact of pharmacist-led care on clinical outcomes. Keywords: High-Risk Medications; Intensive Care Units; Infusions; Patient Safety

Methods: Seventeen phytoconstituents of G. hirsutum were selected for molecular docking against the gastric H+/K+-ATPase structure obtained from the Protein Data Bank (PDB ID: 5YLU). Ligands and protein were prepared using appropriate molecular modelling tools, and docking was performed using AutoDock Vina through PyRx. Protein-ligand interactions were subsequently examined using BIOVIA Discovery Studio Visualizer. Physicochemical and drug-likeness characteristics were evaluated using SwissADME. Results: The docking study will identify phytoconstituents exhibiting favorable predicted binding affinities toward gastric H+/K+-ATPase. The compounds showing the most favorable docking scores and relevant interactions with the receptor will be considered priority candidates for further investigation. Drug-likeness analysis will provide additional information regarding their physicochemical properties and compliance with commonly used medicinal-chemistry filters. Conclusion: The proposed computational investigation provides a preliminary structure-based assessment of G. hirsutum phytoconstituents against gastric H+/K+-ATPase. Compounds demonstrating favorable docking profiles may serve as candidates for subsequent experimental evaluation. However, molecular docking predictions alone cannot establish antiulcer efficacy, pharmacological activity, bioavailability, or safety and therefore require validation through appropriate in vitro and in vivo studies.